RECURRENT SALIVARY GLAND CARCINOMA
Clinical trials for RECURRENT SALIVARY GLAND CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT SALIVARY GLAND CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT SALIVARY GLAND CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Major trial tests drug combo in fight against advanced head and neck cancer
Disease control OngoingThis large, late-stage trial is testing whether adding the drug bevacizumab to standard chemotherapy helps patients with advanced head and neck cancer that has returned or spread. The study enrolled 403 participants to see if the combination helps people live longer or slows canc…
Matched conditions: RECURRENT SALIVARY GLAND CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New drug combo tested to fight advanced salivary gland cancer
Disease control OngoingThis study is testing whether combining two existing drugs can help control advanced salivary gland cancer. It is for adults whose cancer has come back after treatment or has spread to other parts of the body. The goal is to see if the combination of a chemotherapy drug (pemetrex…
Matched conditions: RECURRENT SALIVARY GLAND CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
New drug combo aims to halt rare, Tough-to-Treat cancer
Disease control OngoingThis study is testing whether a combination of two hormone-blocking drugs can control a rare and difficult-to-treat cancer of the salivary glands. It is for adults whose cancer has returned after treatment or has spread, and whose tumors test positive for a specific hormone recep…
Matched conditions: RECURRENT SALIVARY GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC